Compare MPTI & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MPTI | SWKH |
|---|---|---|
| Founded | 1965 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Diversified Financial Services |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.2M | 175.5M |
| IPO Year | N/A | 1999 |
| Metric | MPTI | SWKH |
|---|---|---|
| Price | $52.21 | $17.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 30.4K | 12.6K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 19.64 | ★ 120.89 |
| EPS | ★ 2.40 | 1.85 |
| Revenue | ★ $52,989,000.00 | $40,149,000.00 |
| Revenue This Year | $12.06 | $52.93 |
| Revenue Next Year | $11.80 | N/A |
| P/E Ratio | $21.39 | ★ $9.26 |
| Revenue Growth | 12.79 | ★ 62.38 |
| 52 Week Low | $34.50 | $13.17 |
| 52 Week High | $71.00 | $20.49 |
| Indicator | MPTI | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 50.35 | 59.24 |
| Support Level | $49.50 | $16.69 |
| Resistance Level | $51.80 | $17.75 |
| Average True Range (ATR) | 2.46 | 0.30 |
| MACD | 0.34 | 0.03 |
| Stochastic Oscillator | 82.17 | 58.50 |
M-Tron Industries Inc is a diversified holding company with subsidiaries engaged in designing, manufacturing, and marketing high-engineered, high-reliability frequency and spectrum control products used to control the frequency or timing of signals in electronic circuits in various applications. The company's serving markets are aerospace and defense, space, and avionics. The company offers products such as microwave and millimeter wave filters; cavity, crystal, ceramic, lumped element, and switched filters; crystal resonators, integrated microwave assemblies, and solid-state power amplifier products.
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.